Menu
Recruiting NCT06710405

The Effect of Intraoperative Intravenous Lidocaine Infusion on Postoperative Pain and Recovery in Children (< 7 Years Old) Undergoing Thoracoscopic Surgery

Phase IV Interventional Pain Management After Surgery

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Lidocaine (drug), Saline infusion (placebo).
Who it may be relevant to
Registry conditions: Pain Management After Surgery. Basic parameters: 6 months — 7 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
South Korea
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

The Effect of Intraoperative Intravenous Lidocaine Infusion on Postoperative Pain and Recovery in Children (< 7 Years Old) Undergoing Thoracoscopic Surgery:Prospective, Randomized Controlled Trial

Overview

This study aims to investigate the efficacy of intraoperative intravenous lidocaine infusion on postoperative pain management and recovery in pediatric patients undergoing thoracoscopic pulmonary resection.

Interventions

  • Drug Lidocaine (drug)
    a single bolus dose of lidocaine 1.5 mg/kg is administered concurrently with the induction of anesthesia, followed by a continuous infusion of lidocaine at a rate of 1.5 mg/kg/hr.
  • Drug Saline infusion (placebo)
    Continuous infusion of normal saline in the same volume as that administered to the lidocaine group.

Primary outcome measures

  • FLACC (ace, Legs, Activity, Cry, Consolability scale) Score [Time frame: up to 1 hour after surgery]
Secondary outcome measures (5)
  • Remifentanil dose [Time frame: throughout surgery (up to 3 hours)]
  • ANI (Analgesia Nociception Index) [Time frame: throughout surgery (up to 3 hours)]
  • FLACC scores [Time frame: 6 hours, 12 hours, and 24 hours postoperatively]
  • Total analgesic dosage administered postoperatively [Time frame: up to 3 days after surgery]
  • Postoperative complications [Time frame: until discharge (up to 3-4 days after surgery)]

Eligibility criteria

Inclusion criteria

  • Pediatric patients aged under 7 years undergoing thoracoscopic pulmonary resection

Exclusion criteria

  • cardiac dysfunction requiring vasopressors or inotropic agents
  • atrioventricular block or bradycardia
  • Liver or kidney dysfunction
  • Hypersensitivity to local anesthetics

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

South Korea · 1 center
  • Seoul National University Hospital — Seoul

Identifiers

NCT: NCT06710405 · H2409-100-1573

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗